Masters of Longevity - The Pulse

Youtube — Siim Land23 Oct 2026
The New Tooth Regrowth Breakthrough You Need to Know About (Youtube — Siim Land)

The New Tooth Regrowth Breakthrough You Need to Know About

The speaker says TRG035 completed a Japanese phase 1 and is entering phase 2A for congenital tooth agenesis.

Key takeaways
  • The speaker reports that TRG035 is moving toward Phase 2A.
  • The speaker reports new tooth formation in animal experiments.
  • Human adult tooth regrowth remains unproven by these reported findings.
Longevity Technology23 Oct 2026
Big Pharma, clocks and clinics converge at 7th TimePie Forum (Longevity Technology)

Big Pharma, clocks and clinics converge at 7th TimePie Forum

Presenters linked aging clocks, regenerative trials and clinical longevity evidence needs in Shanghai.

Key takeaways
  • Trials showed biological changes, with limited patient functional gains.
  • Researchers presented new ageing measures and AI tissue analyses.
  • Longevity clinics are expanding while gaps in evidence remain.
BioSpace - Funding23 Oct 2026
Precisio Biotix Therapeutics Receives Additional Funding to Advance a New Approach to Bacterial Vaginosis (BV), A Major Women’s Health Issue (BioSpace - Funding

Precisio Biotix Therapeutics Receives Additional Funding to Advance a New Approach to Bacterial Vaginosis (BV), A Major Women’s Health Issue

Precisio received funding for engineered proteins targeting bacteria linked to bacterial vaginosis. The programme remains preclinical.

Key takeaways
  • This preclinical programme has not established benefits in patients.
  • The proteins are designed to target bacteria within biofilms.
  • The approach aims to preserve microbes considered beneficial.
Longevity Technology23 Oct 2026
AIMuna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial (Longevity Technology)

Muna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial

Muna reported initial tolerability and target-engagement findings for its experimental TREM2 drug. Patient benefit remains unproven.

Key takeaways
  • MNA-001 was well tolerated in an early healthy-volunteer trial.
  • Dose-dependent changes in soluble TREM2 biomarkers were reported.
  • Biomarker shifts have not established clinical benefit in patients.
MoL Event Pick
THE LIVE Barcelona 2026 (Barcelona, Spain)

THE LIVE Barcelona 2026

26. OCT 2026 - 28. OCT 2026 - Barcelona, SpainSummit

International summit where private capital meets longevity: 100+ family offices, UHNW principals and investors from 25+ countries, across Wealth, Living, Security and Future.